<- Go home

Added to YB: 2025-04-04

Pitch date: 2025-02-15

GLPG [bullish]

Galapagos NV

+18.29%

current return

Author Info

No bio for this author

Company Info

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

Market Cap

EUR 1.8B

Pitch Price

EUR 26.79

Price Target

33.00 (+4%)

Dividend

N/A

EV/EBITDA

4.56

P/E

-4.05

EV/Sales

-4.33

Sector

Biotechnology

Category

special_situation

Show full summary:
GALAPAGOS NV - $GLPG

GLPG: Spin-off creates $2.5B SpinCo for acquisitions & $250M ParentCo for cell therapy. 30% upside potential. Activist Kevin Tang (7.5% stake) pushes for value. Gilead partnership. Risks: execution, cash burn. Catalysts: mid-2025 spin-off, acquisitions. Non-cyclical, asymmetric opportunity.

Read full article (4 min)